About The ASCR Network
- Hits: 2528
The Adult Stem Cell Research (ASCR) Network is an Internet-based project of The Cell Therapy Foundation designed to be a well-maintained and reliable source of information for the public regarding adult stem cell research, as well as to be a community of practice and collaboration among fellow researchers. ASCR publishes the latest scientific news in the adult stem cell arena, identifies the leading researchers in the field, and locates key clinical trials; as well as connects the global community of adult stem cell researchers with one another.
- What are Adult Stem Cells?
- Why is Adult Stem Cell Research Important?
- Get Involved with ASCR Network!
Available Clinical Trials
Multiple additional trials are presently ongoing – please contact Cell Therapy Foundation for additional information or specific inquiries.
Hard to heal bone fractures could benefit from CD34+ stem cell treatment
- Hits: 12
Durham, NC (PRWEB) December 04, 2013
A new study appearing in STEM CELLS Translational Medicine (SCTM) demonstrates the potential of a subset of stem cell called CD34+ in treating hard to heal bone fractures.
While most patients recover from broken bones with little or no complication, up to 10 percent experience fractures that won’t heal. This can lead to a number of debilitating side effects, from infection to bone loss, and it can require extensive treatment involving multiple operations and prolonged hospitalization as well as long-term disability.
Regenerating broken bone using stem cells could offer an answer. Adult human peripheral blood CD34+ cells have been shown to contain an abundance of a type of stem cell called endothelial progenitor cells (EPCs) as well as hematopoietic stem cells, which give rise to all types of blood cells. As such, they could be good candidates for this therapy.
Age shouldn't limit access to transplants for MDS, study suggests
- Hits: 14
Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology.
"This is good evidence that age alone should not limit who should get a transplant for MDS," said Gregory Abel, MD, MPH, a medical oncologist at Dana-Farber. "Calendar age is less important than other measures, such as whether a patient is physically fit enough to get through a transplant, has a lot of comorbidities, and what his or her performance status is."
MDS comprises several types of bone marrow failure causing severe anemia.
Abel, senior author Edwin P. Alyea, MD, and their colleagues analyzed the Dana-Farber experience over 10 years with reduced-intensity conditioning "mini-transplants" in patients with MDS, a group of bone-marrow disorders that generally develop in older adults. The mean age at diagnosis is 71.
NASA, CASIS Make Space Station Accessible for Stem Cell Research Read more here: http://www.sacbee.com/2013/12/06/5977397/nasa-casis-make-space-station.html#storylink=cpy
- Hits: 16
WASHINGTON, Dec. 6, 2013 -- /PRNewswire-USNewswire/ -- NASA and the Center for the Advancement of Science in Space (CASIS) are enabling research aboard the International Space Station that could lead to new stem cell-based therapies for medical conditions faced on Earth and in space.
Scientists will take advantage of the space station's microgravity environment to study the properties of non-embryonic stem cells.
NASA is interested in space-based cell research because it is seeking ways to combat the negative health effects astronauts face in microgravity, including bone loss and muscle atrophy. Mitigation techniques are necessary to allow humans to push the boundaries of space exploration far into the solar system. This knowledge could help people on Earth, particularly the elderly, who are afflicted with similar conditions.
Human Stem Cells Predict Efficacy of Alzheimer Drugs
- Hits: 15
Researchers from the University of Bonn use reprogrammed patient neurons for drug testing
Why do certain Alzheimer medications work in animal models but not in clinical trials in humans? A research team from the University of Bonn and the biomedical enterprise LIFE & BRAIN GmbH has been able to show that results of established test methods with animal models and cell lines used up until now can hardly be translated to the processes in the human brain. Drug testing should therefore be conducted with human nerve cells, conclude the scientists. The results are published by Cell Press in the journal "Stem Cell Reports".
In the brains of Alzheimer patients, deposits form that consist essentially of beta-amyloid and are harmful to nerve cells. Scientists are therefore searching for pharmaceutical compounds that prevent the formation of these dangerous aggregates. In animal models, certain non-steroidal anti-inflammatory drugs (NSAIDs) were found to a reduced formation of harmful beta-amyloid variants. Yet, in subsequent clinical studies, these NSAIDs failed to elicit any beneficial effects.